<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793831</url>
  </required_header>
  <id_info>
    <org_study_id>FMC-CN-121101</org_study_id>
    <nct_id>NCT01793831</nct_id>
  </id_info>
  <brief_title>Standardized Fecal Microbiota Transplantation for Crohn&amp;Apos;s Diseases</brief_title>
  <official_title>Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&amp;Apos;s Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Second Hospital of Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut microbiota is considered to constitute a &quot;microbial organ&quot; which has pivotal roles in
      the intestinal diseases and body's metabolism. Evidence from animal and human studies
      strongly supports the link between intestinal bacteria and inflammatory bowel diseases (IBD).
      Dozens of studies reported its efficacy in treatment of severe Clostridium difficile colitis.
      Preliminary studies using FMT for Ulcerative Colitis (UC), Crohn's diseases (CD), irritable
      bowel syndrome (IBS) and constipation have also met with some success. However, the results
      on CD is very limited. This is an initial step into investigating the potential efficacy of
      fecal bacteriotherapy for CD, the investigators propose to determine the efficiency,
      durability and safety of FMT in a series of 500 patients with CD in ten years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present clinical trial aims to re-establish a gut functionality state of intestinal flora
      through FMT as a therapy for CD (all age range,HBI&gt;4). We established a standard microbiota
      isolation from donated fresh stool in lab. Then the microbiota is transplanted to mid-gut (at
      least below the duodenal papilla) through regular gastroscope. Patients from multi-clinical
      centers in this study will be assigned to receive FMT only once or traditional treatments
      according to associated guidelines and follow-up for at least one year. Blood tests,
      abdominal X-ray, endoscopy and questionnaire will be used to assess participants at study
      start and at study completion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Up to one year</time_frame>
    <description>Clinical remission defined as HBI score â‰¦ 4. The endpoint of follow-up is the time of clinical recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>Up to one year</time_frame>
    <description>Social and medical costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During FMT and ten years after FMT</time_frame>
    <description>All possible adverse events:fever,abdominal pain,infectious diseases and others</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Crohn's Diseases</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard fecal microbiota transplantation, once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional treatments, eg. 5-ASA</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Traditional treatments according to associated guidelines, including 5-ASA, immunomodulatory therapy, corticoids, antibody</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>Standard FMT, once</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-ASA, Prednisone, Azathioprine or Remicade</intervention_name>
    <arm_group_label>Traditional treatments, eg. 5-ASA</arm_group_label>
    <other_name>Mesalamine</other_name>
    <other_name>Corticoids</other_name>
    <other_name>Immunomodulatory therapy</other_name>
    <other_name>Infliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe CD define as HBI score &gt; 4.

          -  Montreal classification: no limitation, except age&gt; 6.

        Exclusion Criteria:

          -  Diagnosis as CD first time or first year.

          -  No history of using 5-ASA, biological or immunomodulatory therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Faming Zhang, MD,PhD</last_name>
    <phone>086-25-58509883</phone>
    <email>fzhang@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huijie Zhang, MD, PhD</last_name>
    <phone>086-25-58509670</phone>
    <email>zhjssm@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faming Zhang, MD, PhD</last_name>
      <phone>086-25-58509883</phone>
      <email>fzhang@njmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Faming Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012 Oct;107(10):1452-9. doi: 10.1038/ajg.2012.93. Review.</citation>
    <PMID>23034604</PMID>
  </reference>
  <reference>
    <citation>Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e. Review.</citation>
    <PMID>23041678</PMID>
  </reference>
  <results_reference>
    <citation>Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World J Gastroenterol. 2013 Nov 7;19(41):7213-6. doi: 10.3748/wjg.v19.i41.7213.</citation>
    <PMID>24222969</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang T, Xiang J, Cui B, He Z, Li P, Chen H, Xu L, Ji G, Nie Y, Wu K, Fan D, Huang G, Bai J, Zhang F. Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease. Oncotarget. 2017 Oct 4;8(51):88894-88903. doi: 10.18632/oncotarget.21491. eCollection 2017 Oct 24.</citation>
    <PMID>29179485</PMID>
  </results_reference>
  <results_reference>
    <citation>He Z, Li P, Zhu J, Cui B, Xu L, Xiang J, Zhang T, Long C, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. Sci Rep. 2017 Jul 6;7(1):4753. doi: 10.1038/s41598-017-04984-z.</citation>
    <PMID>28684845</PMID>
  </results_reference>
  <results_reference>
    <citation>Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, Huang G, Liu Z, Wu P, Fan Z, Ji G, Wang X, Wu K, Fan D, Zhang F. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015 Jan;30(1):51-8. doi: 10.1111/jgh.12727.</citation>
    <PMID>25168749</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>January 7, 2018</last_update_submitted>
  <last_update_submitted_qc>January 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Hospital of Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Faming Zhang</investigator_full_name>
    <investigator_title>Associate professor, Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Crohn's diseases</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Fecal transplantation</keyword>
  <keyword>Fecal bacteriotherapy</keyword>
  <keyword>Fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

